Journal Watch · Science Advances · 2026
Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8<sup>+</sup> T cell function in lung cancer.
Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.
TL;DR
Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.
Key findings
- Acetyldigoxin was identified as a high-affinity LOXL4 inhibitor.
- It softened the ECM, disrupted the mechanosignaling-epigenetic axis, reversed CD8<sup>+</sup> T cell exhaustion, and synergized with anti-PD-1 blockade to achieve durable tumor regression.
- In conclusion, this study uncovers a mechanotransduction-to-epigenetic pathway where LOXL4-driven matrix stiffening induces CD8<sup>+</sup> T cell exhaustion.
- Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.
What they did
Molecular docking was performed to explore Food and Drug Administration-approved agents targeting LOXL4. The results demonstrated that tumor-derived LOXL4 stiffened the ECM, which activates the mechanosensor Piezo1 in CD8<sup>+</sup> T cells, triggering Ca<sup>2+</sup> influx and downstream FAK1-YAP1 signaling. Nuclear YAP1 transactivated YBX1, which recruited the metabolic enzyme ACLY and the histone acetyltransferase KAT2A to exhaustion gene loci, epigenetically reinforcing terminal exhaustion. Conditional knockout of <i>Piezo1</i>, <i>Ybx1</i>, <i>Acly</i>, and <i>Kat2a</i> in murine CD8<sup>+</sup> T cells abolished stiffness-induced exhaustion and suppressed tumor growth.
Full abstract (original)
Background: Extracellular matrix (ECM) stiffness is known to impair T cell function, yet the underpinning molecular cascade remains undefined. This paper investigates the role of lysyl oxidase-like 4 (LOXL4) in ECM stiffening and CD8<sup>+</sup> T cell function in lung cancer. <i>Loxl4</i> knockout and mouse recombinant LOXL4 protein systems, along with <i>Piezo1</i>, <i>Ybx1</i>, <i>Acly</i>, and <i>Kat2a</i> conditional knockout mouse models were established. ECM stiffness was measured by atomic force microscopy, and T cell exhaustion markers were analyzed using flow cytometry. RNA sequencing, ATAC-seq, CUT&Tag, chromatin immunoprecipitation-quantitative polymerase chain reaction, and luciferase assays were used to explore the underlying molecular mechanisms.
What they did: Molecular docking was performed to explore Food and Drug Administration-approved agents targeting LOXL4. The results demonstrated that tumor-derived LOXL4 stiffened the ECM, which activates the mechanosensor Piezo1 in CD8<sup>+</sup> T cells, triggering Ca<sup>2+</sup> influx and downstream FAK1-YAP1 signaling. Nuclear YAP1 transactivated YBX1, which recruited the metabolic enzyme ACLY and the histone acetyltransferase KAT2A to exhaustion gene loci, epigenetically reinforcing terminal exhaustion. Conditional knockout of <i>Piezo1</i>, <i>Ybx1</i>, <i>Acly</i>, and <i>Kat2a</i> in murine CD8<sup>+</sup> T cells abolished stiffness-induced exhaustion and suppressed tumor growth.
Results & conclusions: Acetyldigoxin was identified as a high-affinity LOXL4 inhibitor. It softened the ECM, disrupted the mechanosignaling-epigenetic axis, reversed CD8<sup>+</sup> T cell exhaustion, and synergized with anti-PD-1 blockade to achieve durable tumor regression. In conclusion, this study uncovers a mechanotransduction-to-epigenetic pathway where LOXL4-driven matrix stiffening induces CD8<sup>+</sup> T cell exhaustion. Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.
Abstract © the authors / Science Advances (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/sciadv.aef1694 · PubMed 42726857.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Science Advances study find?
Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.
What type of study is this?
It is a preclinical (animal / model) study, published in Science Advances in 2026. Molecular docking was performed to explore Food and Drug Administration-approved agents targeting LOXL4.
Where can I read the original paper?
The original is at the publisher via DOI 10.1126/sciadv.aef1694. PubMed ID: 42726857. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-loxl4-driven-matrix-stiffening-with-acetyldigoxin-restores-cd8-ef1694/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides